| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock South San Francisco, CA - May 16, 2023 - Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janu..." |
|
| 05/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
| 03/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/17/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results SOUTH SAN FRANCISCO, March 17, 2023 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022. “The wins we celebrated in 2022 further solidify our confidence in efruxifermin as a potential best-in-class FGF21 analog addressing all core drivers of NASH disease progression,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “The statistically significant histology and secondary endpoint results from September's topline HARMONY trial readout followed by E..." |
|
| 03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0.2% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.1% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 8.2% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| PRICE T ROWE ASSOCIATES INC reports a 5.1% stake in AKERO THERAPEUTICS INC |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
SC 13G/A
| GOLDMAN SACHS GROUP INC reports a 1% stake in AKERO THERAPEUTICS, INC |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.9% stake in Akero Therapeutics, Inc. |
| 12/05/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|